Industry News CG Oncology BioSpace
CG Oncology's Bladder Cancer Virus Cuts Recurrence Risk by Two-Thirds in Phase 3
- Topline PIVOT-006 data: the oncolytic immunotherapy cretostimogene cut recurrence risk by 68% versus surveillance in intermediate-risk and high-grade Ta non-muscle-invasive bladder cancer.
- The randomized study enrolled 367 patients; the company reports no grade 3 or higher treatment-related adverse events.
- A second BLA is planned for Q2 2027; full data go to the Society of Urologic Oncology meeting on December 2.
This moves cretostimogene from the BCG-unresponsive niche into a far larger adjuvant population with no approved option, which is what the stock is really pricing. The caveats: the control arm is surveillance, not an active drug, and median follow-up is only 17 months, so durability is open. Compare it against intravesical rivals once full data show how many patients needed repeat dosing.
Source: BioSpace ↗ PIVOT-006 Phase 3 Registrational Trial Demonstrates Unprecedented Improvement in Recurrence-Free Survival (RFS) for Intermediate-Risk and High-Grade Ta Non-Muscle Invasive Bladder Cancer (NMIBC)